Suprax is an antibacterial drug owned by Lupin Ltd. The active ingredient of Suprax is cefixime. It was first approved for market use on 20 February 2013.
The generics of Suprax are anticipated to become available after 14 December, 2028. This is the expiration date of the last patent of Suprax, US9233112 titled 'Pharmaceutical compositions of cefixime'. Hence, the release of Suprax generic is expected after this date.
Suprax is mainly used for treating bacterial infections. The active ingredient, cefixime, fights bacteria in the body.
Suprax, owned by Lupin Ltd., has 1 drug patent, which is set to expire on 14 December 2028. The patent, US9233112, is titled 'Pharmaceutical compositions of cefixime'. With the patent's expiration, the path for Suprax generic will be clear. Below are the details of the patent: